Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine versus midazolam for agitation in substance withdrawal syndrome
IRCT20091116002717N4Phase 3Recruiting
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in substance withdrawal comparing Ketamine with Midazolam (2 arms). Primary endpoints: Clinical evidence for ketamine efficacy, Improve treatment protocols and 2 more. Started Aug 2026; status: recruiting.
02
Drugs
ketaminemidazolam
03
Conditions
substance withdrawal
Beyond the preview
Go deeper on IRCT20091116002717N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20091116002717N4.